Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics (NQ: SRPT )

80.40 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,186
Open 80.40
Bid (Size) 80.34 (1)
Ask (Size) 81.35 (1)
Prev. Close 80.40
Today's Range 80.40 - 80.40
52wk Range 55.25 - 159.84
Shares Outstanding 93,148,652
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Ratings for Sarepta Therapeutics
Via Benzinga
ROSEN, A LEADING NATIONAL FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire

Performance

YTD
-35.60%
-35.60%
1 Month
-25.31%
-25.31%
3 Month
-32.85%
-32.85%
6 Month
-38.91%
-38.91%
1 Year
-31.34%
-31.34%

More News

Read More
3 Monster Stocks in the Making
Via The Motley Fool
3 Stocks You’ll Regret Not Buying Soon: November 2023
Via InvestorPlace
SRPT LOSS ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT
From The Rosen Law Firm PA
Via GlobeNewswire
1 Gene Therapy Stock to Buy and Hold for the Long Haul
Via The Motley Fool
Analyst Ratings for Sarepta Therapeutics
Via Benzinga
Why Sarepta Therapeutics Stock Is Crashing Today
Via The Motley Fool
Catalent's Q1 Performance Beat Expectations: Analyst Says Main Focus On Manufacturing Outlook For Sarepta's Gene Therapy
Via Benzinga
Jim Cramer Likes Founder Of AI Company, But Stock Is 'Losing A Fortune' And There's 'Too Much Hype There'
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Is Sarepta Therapeutics Stock a Bad-News Buy?
Via The Motley Fool
Is It Time to Buy the Nasdaq's 4 Worst-Performing October Stocks?
Via The Motley Fool
SRPT LOSS ALERT: ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT
Via NewMediaWire
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review
Via Investor's Business Daily
Sarepta Therapeutics to Present at the UBS Biopharma Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics (SRPT) Q3 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
What's Going On With Biotech Contract Service Firm Catalent Stock Today?
Via Benzinga
Earnings Scheduled For November 1, 2023
Via Benzinga
Uphill Battle Ahead For Gene Therapy Player Sarepta, Analysts Lower Price Targets Following Duchenne Trial Miss
Via Benzinga
Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT
From The Rosen Law Firm, P.A.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.